Theralink (THER) POS AM 26 Aug 16 Prospectus update (post-effective amendment) Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	OncBioMune Pharmaceuticals, Inc
Entity Central Index Key	1,362,703
Document Type	POS AM
Document Period End Date	Jun. 30, 2016
Amendment Flag	false
Trading Symbol	OBMP
Entity Filer Category	Smaller Reporting Company

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
CURRENT ASSETS:
Cash	$ 12,793	$ 672,769	$ 100,760
Due from related parties	2,592	17,800
Prepaid expenses and other current assets	76,669	18,968
Total Current Assets	92,054	709,537	100,760
OTHER ASSETS:
Property and equipment, net	10,153	10,702
Security deposit	6,400	6,400
TOTAL ASSETS	108,607	726,639	100,760
CURRENT LIABILITIES:
Loans payable - related party			46,100
Line of credit	57,741	49,708	34,981
Accounts payable	133,939	102,273
Accrued liabilities	68,480	19,277
Derivative liability	180,506
Convertible promissory note, Net	4,167
Payroll liabilities			18,474
Accounts payable and accrued liabilities		121,550	140,028
Total Current Liabilities	444,833	171,258	239,583
STOCKHOLDERS' EQUITY:
Common stock	5,744	5,711	4,700
Additional paid-in capital	1,811,557	1,678,789	(4,700)
Accumulated deficit	(2,153,627)	(1,129,219)	(138,823)
Total Stockholders' Equity	(336,226)	555,381	(138,823)
Total Liabilities and Stockholders' Equity	108,607	726,639	100,760
Series A Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Preferred stock	$ 100	100
Total Stockholders' Equity		$ 100

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000,000	20,000,000	20,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000	500,000,000
Common stock, shares issued	57,436,191	57,107,809	47,000,000
Common stock, shares outstanding	57,436,191	57,107,809	47,000,000
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Preferred stock, shares issued		1,000,000
Preferred stock, shares outstanding		1,000,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
REVENUES						$ 254
OPERATING EXPENSES:
Professional fees	184,096	14,500	311,099	27,250	213,838	37,293
Compensation expense	156,331	41,317	369,618	71,272	326,274	202,962
Research and development expense	50,449	14,133	80,535	14,148	85,323	151,255
General and administrative expenses	37,748	6,284	111,373	12,991	182,210	61,188
Total Operating Expenses	428,624	76,234	872,625	125,661	807,645	452,698
LOSS FROM OPERATIONS	(428,624)	(76,234)	(872,625)	(125,661)	(807,645)	(452,444)
OTHER INCOME (EXPENSE):
Interest expense	(6,938)	(447)	(7,277)	(873)	(2,479)	(1,989)
Derivative expense	(144,506)		(144,506)
Offering costs					(205,000)
Other		400		6,000	24,728	554
Total Other Income (Expense)	(151,444)	(47)	(151,783)	5,127	(182,751)	(1,435)
NET LOSS	$ (580,068)	$ (76,281)	$ (1,024,408)	$ (120,534)	$ (990,396)	$ (453,879)
NET LOSS PER COMMON SHARE - Basic and Diluted:	$ (0.01)	$ 0	$ (0.02)	$ 0	$ (0.02)	$ (0.01)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic and diluted	57,341,686	47,000,000	57,261,899	47,000,000	49,273,491	47,000,000

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2013		$ 4,700	$ (4,700)	$ 315,056	$ 315,056
Balance, shares at Dec. 31, 2013		47,000,000
Net loss				(453,879)	(453,879)
Balance at Dec. 31, 2014		$ 4,700	(4,700)	(138,823)	(138,823)
Balance, shares at Dec. 31, 2014		47,000,000
Net loss				(990,396)	(990,396)
Recapitalization of Company	$ 100	$ 450	99,527		100,077
Recapitalization of Company, shares	1,000,000	4,493,390
Common shares issued for offering costs		$ 100	204,900		205,000
Common shares issued for offering costs, shares		1,000,000
Common stock issued for services		$ 6	17,994		$ 18,000
Common stock issued for services, shares		60,000			60,000
Shares issued for cash		$ 455	1,361,068		$ 1,361,523
Shares issued for cash, shares		4,554,419			4,493,390
Balance at Dec. 31, 2015	$ 100	$ 5,711	$ 1,678,789	$ (1,129,219)	$ 555,381
Balance, shares at Dec. 31, 2015	1,000,000	57,107,809
Net loss					(1,024,408)
Common stock issued for services					68,000
Balance at Jun. 30, 2016					$ (336,226)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (1,024,408)	$ (120,534)	$ (990,396)	$ (453,879)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	549		274
Stock-based offering costs			205,000
Stock-based compensation	35,000		18,000
Amortization of debt discount	4,167
Derivative expense	144,506
Change in operating assets and liabilities:
Due from related parties	15,208	(3,150)	(17,800)
Prepaid expenses and other current assets	(6,701)		(18,968)	7,000
Accounts payable	133,939	153
Accrued liabilities	(53,070)	(47,403)
Security deposit			(6,400)
Payroll liabilities			(18,474)	(153)
Accounts payable and accrued liabilities			(23,077)	28,820
NET CASH USED IN OPERATING ACTIVITIES	(750,810)	(170,934)	(851,841)	(418,212)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash received in recapitalization			4,676
Acquisition of property and equipment			(10,976)
NET CASH USED IN INVESTING ACTIVITIES			(6,300)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Foundation loans			51,550	45,100
Payments to Foundation loans			(97,650)	(29,000)
Proceeds from related party advances		18,000
Payments of related party advances		(11,000)	(124,350)	(29,000)
Proceeds from line of credit	11,692	19,000	68,355	53,981
Payments to line of credit	(3,659)	(26,050)	(53,628)	(19,000)
Proceeds from convertible debt	36,000	100,000	100,000
Proceeds from sale of common stock	46,801		1,361,523
NET CASH PROVIDED BY FINANCING ACTIVITIES	90,834	99,950	1,430,150	51,081
NET DECREASE IN CASH	(659,976)	(70,984)	572,009	(367,131)
CASH, beginning of year	672,769	100,760	100,760	467,891
CASH, end of year	12,793	29,776	672,769	100,760
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest	339	873	2,479	895
Income taxes
Non-cash investing and financing activities:
Conversion of debt as part of recapitalization			100,000
Increase in debt discount and derivative liability	36,000
Issuance of common stock for services	$ 68,000		$ 18,000

Organization and Nature of Oper

Organization and Nature of Operations	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS OncBioMune Pharmaceuticals, Inc. (formerly Quint Media Inc.) (the “Company,” “we,” “us” or “our”) was incorporated under the laws of the State of Nevada on March 18, 2005, as PediatRx, Inc. From July 23, 2010 until early fiscal year 2014, the Company engaged in the pharmaceutical business. During the fiscal year ended February 28, 2014, the Company decided to divest itself of the balance of its pharmaceutical assets and engage in the digital media business, which encompasses social discovery aspects of the internet, primarily through an engagement website with mobile and tablet applications. On June 22, 2015 and amended and effective on September 2, 2015, the Company entered into a share exchange agreement (the “Exchange Agreement”) with OncBioMune, Inc. (“ONC”) and the shareholders of ONC. Pursuant to the Exchange Agreement, the Company acquired 100% of ONC’s issued and outstanding common stock from the ONC shareholders in exchange for the issuance of 47,000,000 shares of the Company’s common stock, representing 91.3% of the outstanding common stock, and 1,000,000 shares of the Company’s Series A Preferred Stock, representing 100% of the outstanding Series A Preferred Stock, (the “Exchange”), after giving effect to a 1-for-139.2328 reverse stock split (the “Reverse Stock Split”) which resulted in 4,493,390 common shares outstanding prior to the Exchange. Accordingly, the ONC shareholders became shareholders of the Company and ONC became a subsidiary of the Company. The Exchange has been accounted for as a reverse-merger and recapitalization since the stockholders of ONC obtained voting and management control of the Company. ONC is the acquirer for financial reporting purposes and the Company is acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Exchange are those of ONC and was recorded at the historical cost basis of ONC, and the consolidated financial statements after completion of the Share Exchange included the assets and liabilities of both the Company and ONC and the Company’s consolidated operations from the closing date of the Share Exchange. All share and per share data in the accompanying consolidated financial statements have been retroactively restated to reflect the effect of the Reverse Stock Split and recapitalization. ONC was formed under the laws of the State of Louisiana in March 2005 as a limited liability company. On June 3, 2015 ONC converted from a Louisiana limited liability company to a Louisiana corporation. ONC is a biotechnology company specializing in innovative cancer treatment therapies. ONC has proprietary rights to a breast and prostate patent vaccine, as well as a process for the growth of cancer tumors. ONC’s mission is to improve the overall patient condition through innovative bio immunotherapy with proven treatment protocols, to lower deaths associated with cancer and reduce the cost of cancer treatment. ONC’s technology is safe, and utilizes clinically research proven methods of treatment to provide optimal success of patient recovery. On August 12, 2015, the Company filed amended and restated Articles of Incorporation with the Nevada Secretary of State which: a. changed the Company’s name to OncBioMune Pharmaceuticals, Inc.; b. amended the authorized shares of the Company to 520,000,000, of which 500,000,000 shares are common stock, with a par value of $0.0001 per share (“Common Stock”), and 20,000,000 shares are preferred stock, with a par value of $0.0001 per share (“Preferred Stock”); and c. effected the Reverse Stock Split, which became effective on August 27, 2015. On August 20, 2015, the Company filed the Certificate of Designation with the Nevada Secretary of State, designating 1,000,000 shares of the authorized 20,000,000 Preferred Stock as Series A Preferred Stock (“Series A Preferred Stock”). Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth in the Certificate of Designation) for the taking of any corporate action. Basis of presentation and principles of consolidation The Company’s consolidated financial statements include the financial statements of its wholly owned subsidiary, ONC. All significant intercompany accounts and transactions have been eliminated in consolidation Management acknowledges its responsibility for the preparation of the accompanying unaudited condensed consolidated financial statements which reflect all adjustments, consisting of normal recurring adjustments, considered necessary in its opinion for a fair statement of its financial position and the results of its operations for the periods presented. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”) for interim financial information and with the instructions Article 8-03 of Regulation S-X. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements These unaudited condensed financial statements should be read in conjunction with the summary of significant accounting policies and notes to the financial statements for the years ended December 31, 2015 and 2014 of ONC which were included in the Company’s annual report on Form 10-K as filed with the Securities and Exchange Commission on April 13, 2016. Going concern These consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying unaudited condensed consolidated financial statements, the Company had a net loss of $1,024,408 and $120,534 for the six months ended June 30, 2016 and 2015, respectively. The net cash used in operations were $750,810 and $170,934 for six months ended June 30, 2016 and 2015, respectively. Additionally, the Company had an accumulated deficit of $2,153,627 and $1,129,219, at June 30, 2016 and December 31, 2015, and had no revenues for the six months ended June 30, 2016 and 2015. Effective September 2, 2015, the Company entered into the Exchange Agreement which changed the nature of its business and management. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. Management believes that the Company’s capital resources are not currently adequate to continue operating and maintaining its business strategy for the fiscal year ending December 31, 2016. The Company will seek to raise capital through additional debt and/or equity financings to fund its operations in the future. Although the Company has historically raised capital from sales of equity and from the issuance of promissory notes, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail or cease operations. These unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.	NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION Organization OncBioMune Pharmaceuticals, Inc. (formerly Quint Media Inc.) (the “Company,” “we,” “us” or “our”) was incorporated under the laws of the State of Nevada on March 18, 2005, as PediatRx, Inc. From July 23, 2010 until early fiscal year 2014, the Company engaged in the pharmaceutical business. During the fiscal year ended February 28, 2014, the Company decided to divest itself of the balance of its pharmaceutical assets and engage in the digital media business, which encompasses social discovery aspects of the internet, primarily through an engagement website with mobile and tablet applications. On June 22, 2015 and amended and effective on September 2, 2015, the Company entered into a share exchange agreement (the “Exchange Agreement”) with OncBioMune, Inc. (“ONC”) and the shareholders of ONC. Pursuant to the Exchange Agreement, the Company acquired 100% of ONC’s issued and outstanding common stock from the ONC shareholders in exchange for the issuance of 47,000,000 shares of the Company’s common stock, representing 91.3% of the outstanding common stock, and 1,000,000 shares of the Company’s Series A Preferred Stock, representing 100% of the outstanding series A Preferred Stock, (the “Exchange”), after giving effect to a 1-for-139.2328 reverse stock split (the “Reverse Stock Split”) which resulted in 4,493,390 common shares outstanding prior to the Exchange. Accordingly, the ONC shareholders became shareholders of the Company and ONC became a subsidiary of the Company. The Exchange has been accounted for as a reverse-merger and recapitalization since the stockholders of ONC obtained voting and management control of the Company. ONC is the acquirer for financial reporting purposes and the Company is acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Exchange are those of ONC and was recorded at the historical cost basis of ONC, and the consolidated financial statements after completion of the Share Exchange included the assets and liabilities of both the Company and ONC and the Company’s consolidated operations from the closing date of the Share Exchange. All share and per share data in the accompanying consolidated financial statements have been retroactively restated to reflect the effect of the Reverse Stock Split and recapitalization. ONC was formed under the laws of the State of Louisiana in March 2005 as a limited liability company. On June 3, 2015 ONC converted from a Louisiana limited liability company to a Louisiana corporation. ONC is a biotechnology company specializing in innovative cancer treatment therapies. ONC has proprietary rights to a breast and prostate patent vaccine, as well as a process for the growth of cancer tumors. ONC’s mission is to improve the overall patient condition through innovative bio immunotherapy with proven treatment protocols, to lower deaths associated with cancer and reduce the cost of cancer treatment. ONC’s technology is safe, and utilizes clinically research proven methods of treatment to provide optimal success of patient recovery. On August 12, 2015, the Company filed amended and restated Articles of Incorporation with the Nevada Secretary of State which: a. changed the Company’s name to OncBioMune Pharmaceuticals, Inc., b. amended the authorized shares of the Company to 520,000,000, of which 500,000,000 shares are common stock, with a par value of $0.0001 per share (“Common Stock”), and 20,000,000 shares are preferred stock, with a par value of $0.0001 per share (“Preferred Stock”), and c. effected the Reverse Stock Split, which became effective on August 27, 2015. On August 20, 2015, the Company filed the Certificate of Designation with the Nevada Secretary of State, designating 1,000,000 shares of the authorized 20,000,000 Preferred Stock as Series A Preferred Stock (“Series A Preferred Stock”). Each holder of Series A Preferred Stock shall be entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent shall not be required (except to the extent they are entitled to vote with holders of Common Stock as set forth in the Certificate of Designation) for taking any corporate action. Basis of presentation and principles of consolidation The Company’s consolidated financial statements include the financial statements of its wholly-owned subsidiary, ONC. All significant intercompany accounts and transactions have been eliminated in consolidation The accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”). Going concern These consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, the Company had a net loss of $990,396 and $453,879 for the year ended December 31, 2015 and 2014, respectively. The net cash used in operations were $851,841 and $418,212 for the year ended December 31, 2015 and 2014, respectively. Additionally, the Company had an accumulated deficit of $1,129,219 at December 31, 2015, and no revenue for the year ended December 31, 2015. Effective September 2, 2015, the Company entered into the Exchange Agreement which changed the nature of its business and management. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. Management believes that the Company’s capital resources are not currently adequate to continue operating and maintaining its business strategy for the fiscal year ending December 31, 2015. The Company will seek to raise capital through additional debt and/or equity financings to fund its operations in the future. Although the Company has historically raised capital from sales of equity and from the issuance of promissory notes, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail or cease operations. These consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates during the six months ended June 30, 2016 and 2015 include the useful life of property and equipment, assumptions used in assessing impairment of long-term assets, estimates of current and deferred income taxes and deferred tax valuation allowances and the fair value of non-cash equity transactions. Fair value of financial instruments and fair value measurements The Company adopted the guidance of Accounting Standards Codification (“ASC”) 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: ● Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. ● Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. ● Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The carrying amounts reported in the consolidated balance sheets for cash, employee loans, prepaid expenses, loans payable, line of credit payable, payroll liabilities, and accounts payable and accrued liabilities, approximate their fair market value based on the short-term maturity of these instruments. The Company did not identify any assets or liabilities that are required to be presented on the consolidated balance sheets at fair value in accordance with ASC Topic 820. ASC 825-10 “ Financial Instruments , Stock-based compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is recognized over the service period of the award. Basic and diluted earnings per share Pursuant to ASC 260-10-45, basic earnings per common share is computed by dividing income (loss) available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted income per share is computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. Diluted income (loss) per share reflects the potential dilution that could occur if securities were exercised or converted into common stock or other contracts to issue common stock resulting in the issuance of common stock that would then share in the Company’s income (loss) subject to anti-dilution limitations. Potentially dilutive common shares consist of common stock issuable for stock warrants (using the treasury stock method). These common stock equivalents may be dilutive in the future. All potentially dilutive common shares were excluded from the computation of diluted shares outstanding as they would have an anti-dilutive impact on the Company’s net losses and consisted of the following: June 30, 2016 June 30, 2015 Total stock warrants 2,694 2,694 Recent accounting pronouncements In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern, In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes Income Taxes On January 5, 2016, the FASB issued ASU No. 2016-01 to amend the accounting guidance on the classification and measurement of financial instruments. The standard requires that all investments in equity securities, including other ownership interests, are carried at fair value through net income. This requirement does not apply to investments that qualify for equity method accounting or to those that result in consolidation of the investee or for which the entity has elected the predictability exception to fair value measurement. Additionally, the standard requires that the portion of the total fair value change caused by a change in instrument-specific credit risk for financial liabilities for which the fair value option has been elected would be recognized in other comprehensive income. Any accumulated amount remaining in other comprehensive income is reclassified to earnings when the liability is extinguished. The Company does not anticipate the guidance to have a material impact on its consolidated financial statements or notes to its consolidated financial statements. On February 25, 2016, the FASB issued ASU No. 2016-02 (“ASU 2016-02”) to amend the accounting guidance for leases. The accounting applied by a lessor is largely unchanged under ASU 2016-02. However, the standard requires lessees to recognize lease assets and lease liabilities for leases classified as operating leases on the balance sheet. Lessees will recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it will recognize lease expense for such leases generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and early adoption is permitted. The Company is currently assessing the impact of the guidance on its consolidated financial statements and notes to its consolidated financial statements. On March 30, 2016, the FASB issued ASU No. 2016-09 (“ASU 2016-09”) to amend the accounting guidance for share-based payment accounting. The areas for simplification in ASU 2016-09 involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016 Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of estimates The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates during the year ended December 31, 2015 and December 31, 2014 include the useful life of property and equipment, assumptions used in assessing impairment of long-term assets, estimates of current and deferred income taxes and deferred tax valuation allowances and the fair value of non-cash equity transactions. Fair value of financial instruments and fair value measurements The Company adopted the guidance of Accounting Standards Codification (“ASC”) 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: ● Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. ● Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. ● Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The carrying amounts reported in the consolidated balance sheets for cash, employee loans, prepaid expenses, loans payable, line of credit payable, payroll liabilities, and accounts payable and accrued liabilities, approximate their fair market value based on the short-term maturity of these instruments. The Company did not identify any assets or liabilities that are required to be presented on the consolidated balance sheets at fair value in accordance with ASC Topic 820. ASC 825-10 “ Financial Instruments , Cash and Cash Equivalent For purposes of the consolidated statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less at the purchase date and money market accounts to be cash equivalents. At December 31, 2015 and 2014, the Company did not have any cash equivalents. The Company maintains its cash in bank and financial institution deposits that at times may exceed federally insured limits. At December 31, 2015, cash in bank exceeded federally insured limits. There were no balances in excess of FDIC insured levels as of December 31, 2014. The Company has not experienced any losses in such accounts through December 31, 2015 and 2014. Property and equipment Property are stated at cost and are depreciated using the straight-line method over their estimated useful lives, which range from three to ten years. Leasehold improvements are depreciated over the shorter of the useful life or lease term including scheduled renewal terms. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. Impairment of long-lived assets In accordance with ASC Topic 360, the Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. Revenue recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the purchase price is fixed or determinable and collectability is reasonably assured. For all revenue sources discussed below, in accordance ASC 605-45 “Principal Agent Considerations”, the Company recognizes revenue net of amounts retained by third party entities. Federal and state income taxes The Company accounts for income tax using the liability method prescribed by ASC 740, “Income Taxes”. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. Prior to the June 3, 2015, the Company operated ONC as a limited liability company and passed all income and loss to each member based on their proportionate interest in ONC. In accordance with the generally accepted method of presenting limited liability company financial statements, the consolidated financial statements do not include the personal assets and liabilities of the members, including their obligation for income taxes on their distributive shares of net income of the LLCs, or any provision for federal income taxes prior to June 3, 2015. The Company follows the accounting guidance for uncertainty in income taxes using the provisions of Accounting Standards Codification (ASC) 740 “Income Taxes Research and development Research and development costs incurred in the development of the Company’s products are expensed as incurred. For the years ended December 31, 2015 and 2014, research and development costs were $85,323 and $151,255, respectively, and are included in operating expenses on the accompanying consolidated statements of operations. Stock-based compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is recognized over the service period of the award. Basic and diluted earnings per share Pursuant to ASC 260-10-45, basic earnings per common share is computed by dividing income (loss) available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted income per share is computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. Diluted income (loss) per share reflects the potential dilution that could occur if securities were exercised or converted into common stock or other contracts to issue common stock resulting in the issuance of common stock that would then share in the Company’s income (loss) subject to anti-dilution limitations. Potentially dilutive common shares consist of common stock issuable for stock warrants (using the treasury stock method). These common stock equivalents may be dilutive in the future. All potentially dilutive common shares were excluded from the computation of diluted shares outstanding as they would have an anti-dilutive impact on the Company’s net losses and consisted of the following: December 31, 2015 December 31, 2014 Total stock warrants 2,694 0 Recent accounting pronouncements In June 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-12, “ Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period In August 2014, FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, In February 2015, the FASB issued ASU 2015-02, Consolidation In April 2015, the FASB issued ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30) In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes Income Taxes Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 3 - PROPERTY AND EQUIPMENT At December 31, 2015 and 2014, property and equipment consisted of the following: Useful Life 2015 2014 Leasehold improvements 10 Years $ 23,976 $ - Less: accumulated depreciation (13,274 ) - Property and equipment, net $ 10,702 $ 0 For the years ended December 31, 2015 and 2014, depreciation and amortization expense amounted to $274 and $0, respectively.

Line of Credit

Line of Credit	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Line of Credit	NOTE 3 – LINE OF CREDIT In October 2014, ONC entered into a $100,000 revolving promissory note (the “Revolving Note”) with Regions Bank (the “Lender”). The unpaid principal balance of the Revolving Note is payable on demand and any unpaid principal and interest is payable due not later than October 27, 2017, is secured by deposits located at the Lender, and bears interest computed at a variable rate of interest which is equal to the Lender’s prime rate plus 1.7% (5.20% and 5.20% at June 30, 2016 and December 31, 2015, respectively). ONC will pay to Lender a late charge of 5.0% of any monthly payment not received by Lender within 10 calendar days after its due date. The Company may, at any time or from time to time, prepay the Revolving Note in whole or in part without penalty. At June 30, 2016 and December 31, 2015, the Company had $57,741 and $49,708, respectively, in borrowings outstanding under the Revolving Note with $42,259 and $50,292, respectively, available for borrowing under such note. The weighted average interest rate during the six months ended June 30, 2016 was approximately 5.20%.	NOTE 4 – LINE OF CREDIT In October 2014, ONC entered into a $100,000 revolving promissory note (the “Revolving Note”) with Regions Bank (the “Lender”). The unpaid principal balance of the Revolving Note is payable on demand and any unpaid principal and interest is payable due not later than October 27, 2017, is secured by deposits located at the Lender, and bears interest computed at a variable rate of interest which is equal to the Lender’s prime rate plus 1.7% (5.20% and 4.95% at December 31, 2015 and 2014, respectively). ONC will pay to Lender a late charge of 5.0% of any monthly payment not received by Lender within 10 calendar days after its due date. The Company may, at any time or from time to time, prepay the Revolving Note in whole or in part without penalty. At December 31, 2015 and 2014, the Company had $49,708 and $34,981, respectively, in borrowings outstanding under the Revolving Note with $50,292 and $65,019, respectively, available for borrowing under such note. The weighted average interest rate during the years ended December 31, 2015 and 2014 was approximately 4.95% and 4.95%, respectively.

Convertible Promissory Note

Convertible Promissory Note	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Convertible Promissory Note	NOTE 4 – CONVERTIBLE PROMISSORY NOTE On May 23, 2016, the Company entered into a $40,000 convertible promissory note (the “Convertible Note”) with Crown Bridge Partners, LLC (the “Lender”). The unpaid principal and interest is payable no later than May 22, 2017 and bears interest computed at a rate of interest which is equal to 8.0% per annum. Any amount of principal or interest on this Convertible Note, which is not paid by the maturity date, shall bear interest at the rate of 22% per annum from the due date until paid. The Company may prepay any amount outstanding under the Convertible Note by making a payment to the Lender of an amount in cash equal as follow: Time Frame after Convertible Note Date Prepayment Penalty Amount Initial 30 day period 115% multiplied the amount of prepayment 31st to 60th day 120% multiplied the amount of prepayment 61st to 90th day 125% multiplied the amount of prepayment 91st to 120th day 130% multiplied the amount of prepayment 120th to 150th day 135% multiplied the amount of prepayment 151st to l80th day 140% multiplied the amount of prepayment The prepayment is subject to the Lender’s prior written acceptance in the Lender’s sole discretion. The Company may not prepay any amount outstanding under the Convertible Note after the 180 th The Lender is entitled, at their option, at any time after the issuance of the Convertible Note, to convert all or any lesser portion of the outstanding principal amount and accrued but unpaid interest into the Company’s common stock. The Conversion Price is the Variable Conversion Price (“VCP”) as defined in the Convertible Note and subject, in each case, to equitable adjustments for stock splits, stock dividends or rights offerings by the Company relating to the Company’s securities or the securities of any subsidiary of the Company, combinations, recapitalization, reclassifications, extraordinary distributions and similar events. VCP means 58% multiplied by the “Market Price”, which is calculated as the lowest trading price, as defined, for the Company’s common stock during the twenty trading day period ending on the last complete trading day prior to the conversion date. If at any time while the Convertible Note is outstanding, the lowest trading prices for the Company’s common stock is equal to or lower than $0.10, then an additional discount of five percent (5%) will be factored into the VCP until the Convertible Note is no longer outstanding (resulting in a discount rate of 47% assuming no other adjustments are triggered hereunder). In the event that shares of the Company’s common stock are not deliverable via DWAC following the conversion of any amount thereunder, an additional five percent (5%) discount shall be factored into the VCP until the Convertible Note is no longer outstanding (resulting in a discount rate of 47% assuming no other adjustments are triggered hereunder). In connection with the issuance of the Convertible Note above, the Company determined that the terms of the Convertible Note include a down-round provision under which the conversion price and exercise price could be affected by future equity offerings undertaken by the Company or contain terms that are not fixed monetary amounts at inception. Accordingly, under the provisions of FASB ASC Topic No. 815-40, “Derivatives and Hedging – Contracts in an Entity’s Own Stock”, the embedded conversion option contained in the convertible instruments were accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value through earnings at each reporting date. The fair value of the embedded conversion option derivatives was determined using the Black- Scholes Option Pricing Model. On the initial measurement date, the fair values of the embedded conversion option derivative of $76,012 was recorded as a derivative liability and was allocated as a debt discount up to the net proceeds of the Convertible Note of $36,000 with the remainder of $40,012 charged to current period operations as initial derivative expense. At June 30, 2016, the Company valued the embedded conversion option derivative liabilities resulting in a loss from change in fair value of derivative liabilities of $104,494 for the three and six months ended June 30, 2016 which is recorded as a component of other income/(expense) in the accompanying statements of operations. During the six months ended June 30, 2016, the fair value of the derivative liabilities was estimated using the Black-Scholes option-pricing model with the following assumptions: Dividend rate 0 Term (in years) 0.92 to 1.0 years Volatility 366.97 % Risk-free interest rate 0.45% to 0.69 % For the three and six months ended June 30, 2016, amortization of debt discounts related to these convertible note amounted to $4,167 and $4,167, respectively, which has been included in interest expense on the accompanying statements of operations. At June 30, 2016 and December 31, 2015, the Convertible Note consisted of the following: June 30, 2016 December 31, 2015 Principal amount $ 40,000 $ - Less: unamortized debt discount (35,833 ) - Convertible note payable, net $ 4,167 $ - At June 30, 2016, the Company had $40,000, respectively, in borrowings outstanding under the Convertible Note. The weighted average interest rate during the six months ended June 30, 2016 was approximately 8.0%.

Related Party Transactions

Related Party Transactions	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 5 – RELATED-PARTY TRANSACTIONS From time to time, the Company receives advances from and makes advances to The Sallie Astor Burdine Breast Foundation (the “Foundation”), a not-for-profit foundation created by our chief executive officer who is also a board member of the Foundation, for working capital purposes. The advances are non-interest bearing and are payable on demand. From time to time, the Company receives advances from and makes advances to the Company’s chief executive officer and chief financial officer for working capital purposes. The advances are non-interest bearing and are payable on demand. For the six months ended June 30, 2016, due from/(to) related parties’ activity consisted of the following: Foundation CEO CFO Total Balance due from (to) related parties at December 31, 2015 $ 3,200 $ 5,900 $ 8,700 ) $ 17,800 Working capital advances made 3,687 - 3,250 6,937 Repayments received (6,050 ) (5,900 ) (10,195 ) (22,145 ) Balance due from (to) related parties at June 30, 2016 $ 837 $ - $ 1,755 $ 2,592 All balances due from related parties were repaid in August 2016 and the Company does not intend to make such advances in the future.	NOTE 5 – RELATED PARTY TRANSACTIONS Due from/(to) related parties From time to time, the Company receives advances from and makes advances to The Sallie Astor Burdine Breast Foundation (the “Foundation”), a not-for-profit foundation created by our chief executive officer who is also a board member of the Foundation, for working capital purposes. The advances are non-interest bearing and are payable on demand. From time to time, the Company receives advances from and makes advances to the Company’s chief executive officer and chief financial officer for working capital purposes. The advances are non-interest bearing and are payable on demand. For the year ended December 31, 2015 and 2014, due from/(to) related parties activity consisted of the following: Foundation CEO CFO Total Balance due from (to) related party at December 31, 2013 $ (30,000 ) $ - $ - $ (30,000 ) Working capital advances received (45,100 ) - - (45,100 ) Repayments made 29,000 - - 29,000 Balance due from (to) related party at December 31, 2014 (46,100 ) - - (46,100 ) Working capital advances received (48,350 ) (7,500 ) (4,600 ) (60,450 ) Repayments made 97,650 13,400 13,300 124,350 Balance due from (to) related party at December 31, 2015 $ 3,200 $ 5,900 $ 8,700 $ 17,800 All working capital advance made by the Company to these related parties were repaid in March 2016 and the Company does not intend to make such advances in the future.

Stockholders' Deficit

Stockholders' Deficit	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Equity [Abstract]
Stockholders' Deficit	NOTE 6 – STOCKHOLDERS’ DEFICIT Series A Preferred Stock On August 20, 2015, the Company filed the Certificate of Designation with the Nevada Secretary of State, designating 1,000,000 shares of the authorized 20,000,000 Preferred Stock as Series A Preferred Stock. Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for the taking of any corporate action. On September 2, 2015, in connection with the Exchange, the Company issued 1,000,000 shares of the Company’s Series A Preferred Stock, representing 100% of the outstanding Series A Preferred. Common stock issued for services On January 1, 2016, the Company issued 60,000 shares of common stock valued at $.30 per common share or $18,000 to a director for services to be rendered on the Company’s board of directors. The shares were valued at the most recent cash price paid of $.30 per share. In connection with these shares, the Company recorded stock-based compensation of $18,000. On May 13, 2016, the Company entered into a six-month consulting agreement for business development services, Pursuant to the agreement, the Company shall pay the consultant a monthly fee of $4,000 beginning on May 15, 2016 and, thereafter, on the fifteenth day of each month. In addition, the Company issued the consultant and/or its affiliates 200,000 shares of the Company’s common stock. The common shares were valued at the most recent quoted trading price of $0.34 per share or $68,000. In connection with these shares, the Company recorded stock-based consulting expense of $17,000 and prepaid expenses of $51,000 which will be amortized over the remaining service period. If the Company chooses to extend the agreement, the Company shall pay the consultant a monthly fee of $7,500 beginning on November 15, 2016 and, thereafter, on the first of each month and the Company shall issue to the consultant 100,000 Shares of the Company’s common stock. Common stock issued for cash From January 1, 2016 to March 31, 2016, pursuant to subscription agreements, the Company issued 68,382 shares of its common stock to investors for cash proceeds of $46,801.	NOTE 6 – STOCKHOLDERS’ EQUITY Series A Preferred Stock On August 20, 2015, the Company filed the Certificate of Designation with the Nevada Secretary of State, designating 1,000,000 shares of the authorized 20,000,000 Preferred Stock as Series A Preferred Stock. Each holder of Series A Preferred Stock shall be entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent shall not be required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for taking any corporate action. On September 2, 2015, in connection with the Exchange, the Company issued 1,000,000 shares of the Company’s Series A Preferred Stock, representing 100% of the outstanding series A Preferred. Common stock issued in Share Exchange On June 22, 2015 and amended and effective on September 2, 2015, the Company entered into the “Exchange Agreement” with OncBioMune, Inc. (“ONC”) and the shareholders of ONC. Pursuant to the Exchange Agreement, the Company acquired 100% of ONC’s issued and outstanding common stock from the ONC shareholders in exchange for the issuance of 47,000,000 shares of the Company’s common stock, representing 91.3% of the outstanding common stock. Included in the 47,000,000 common shares the Company issued in the Exchange was 200,000 shares of its common stock issued in full satisfaction of convertible debt of $100,000 which has been reflected as part of the recapitalization of the Company. Immediately prior to the Exchange there were 4,493,390 common shares outstanding. Common stock issued for services On November 18, 2015, the Company issued 60,000 shares of common stock valued at $.30 per common share or $18,000 to a director for services to be rendered on the Company’s board of directors. The shares were valued at the most recent cash price paid of $.30 per share. In connection with these shares, the Company recorded stock-based compensation of $18,000. Common stock issued for cash In December 2015, pursuant to subscription agreements, the Company issued 4,221,085 shares of its common stock to investors for cash proceeds of $1,266,523. Common stock purchase agreement On October 20, 2015, the Company entered into a purchase agreement (the “Purchase Agreement”), together with a registration rights agreement (the “Registration Rights Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Upon signing the Purchase Agreement, Lincoln Park agreed to purchase 333,334 shares of the Company’s common stock for $100,000 or $0.30 per share as an initial purchase under the Purchase Agreement. Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right to sell to, and Lincoln Park is obligated to purchase, up to an additional $10.0 million in amounts of shares, as described below, of the Company’s common stock, subject to certain limitations, from time to time, over the 36-month period commencing on the date that a registration statement, which the Company agreed to file with the Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus in connection therewith is filed. The Company may direct Lincoln Park, at its sole discretion and subject to certain conditions, to purchase up to 50,000 shares of Common Stock on any business day (such purchases, “Regular Purchases”), provided that at least one business day has passed since the most recent purchase, and provided, however that Lincoln Park’s committed obligation under any single Regular Purchase shall not exceed Fifty Thousand Dollars ($50,000), provided that the amount the Company may sell to Lincoln Park under a single Regular Purchase may increase under certain circumstances as described in the Purchase Agreement but in no event will the amount of a single Regular Purchase exceed Five Hundred Thousand Dollars ($500,000). The purchase price of shares of Common Stock related to the future funding will be based on the prevailing market prices of such shares at the time of sales. In addition, the Company may direct Lincoln Park to purchase additional amounts as accelerated purchases if on the date of a Regular Purchase the closing sale price of the Common Stock is not below the threshold price as set forth in the Purchase Agreement. The Company’s sales of shares of Common Stock to Lincoln Park under the Purchase Agreement are limited to no more than the number of shares that would result in the beneficial ownership by Lincoln Park and its affiliates, at any single point in time, of more than 4.99% of the then outstanding shares of the Common Stock. In connection with the Purchase Agreement, the Company issued as a commitment fee to Lincoln Park 1,000,000 shares of Common Stock. Lincoln Park represented to the Company, among other things, that it was an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”)), and the Company sold the securities in reliance upon an exemption from registration contained in Section 4(a)(2) under the Securities Act. The securities sold may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Purchase Agreement and the Registration Rights Agreement contain customary representations, warranties, agreements and conditions to completing future sale transactions, indemnification rights and obligations of the parties. The Company has the right to terminate the Purchase Agreement at any time, at no cost or penalty. Actual sales of shares of Common Stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the Common Stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. Lincoln Park has no right to require any sales by the Company, but is obligated to make purchases from the Company as it directs in accordance with the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of our shares. The net proceeds under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park. The Company expects that any proceeds received by the Company from such sales to Lincoln Park under the Purchase Agreement will be used for general corporate purposes and working capital requirements. In November 2015, pursuant to the Purchase Agreement, the Company issued 333,334 shares for net proceeds of $95,000 and issued 1,000,000 shares of common stock to Lincoln Park as a commitment fee. The 1,000,000 shares were value at $300,000 or $0.30 per common shares based on the sale price per share under the Purchase Agreement. In connection with the issuance of the commitment shares, the Company recorded offering costs of $300,000 by reducing net proceeds received under the Purchase Agreement by $95,000 and for the year ended December 31, 2015, the Company recorded offering costs of $205,000 which is reflected on the accompanying consolidated statement of operations

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 7 – INCOME TAXES The Company maintains deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of the attainment of future taxable income. Prior to the June 3, 2015, the Company operated ONC as a limited liability company and passed all income and loss to each member based on their proportionate interest in ONC. In accordance with the generally accepted method of presenting limited liability company financial statements, the consolidated financial statements do not include the personal assets and liabilities of the members, including their obligation for income taxes on their distributive shares of net income of the LLCs, or any provision for federal income taxes prior to June 3, 2015. Accordingly, no provision for federal and state income taxes has been made in these consolidated financial statements for these periods. Had the Company been subject to income taxes during the period from January 2014 to June 3, 2015, the pro forma effect of income taxes on the Company’s net income (loss) based of the Company’s statutory income tax rate of 34% was not material. The items accounting for the difference between income taxes at the effective statutory rate and the provision for income taxes for the years ended December 31, 2015 and 2014 were as follows: Years Ended December 31, 2015 2014 Income tax benefit at U.S. statutory rate of 34% $ (337,000 ) $ - State income taxes bene (79,000 ) - Stock-based compensation 7,000 Income tax effect during LLC period 36,000 - Change in valuation allowance 373,000 - Total provision for income tax $ - $ - The Company’s approximate net deferred tax assets as of December 31, 2015 and 2014 were as follows: December 31, 2015 December 31, 2014 Deferred Tax Assets: Net operating loss carryforward $ 373,000 $ - Total deferred tax assets 373,000 - Valuation allowance (373,000 ) - Net deferred tax assets $ - $ - The estimated net operating loss carryforward was approximately $888,100 at December 31, 2015. The Company’s net operating loss carryforward acquired in the Combination were limitation on the usage of such net operating loss carryforwards due to a change in ownership in accordance with Section 382 of the Internal Revenue Code. The Company provided a valuation allowance equal to the net deferred income tax asset for the year ended December 31, 2015 because it was not known whether future taxable income will be sufficient to utilize the loss carryforward. The increase in the valuation allowance was $373,000 from the year ended December 31, 2015. The potential tax benefit arising from tax loss carryforwards will expire in 2035. The Company does not have any uncertain tax positions or events leading to uncertainty in a tax position. The Company’s 2013, 2014 and 2015 Corporate Income Tax Returns are subject to Internal Revenue Service examination.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 7 – COMMITMENTS Employment agreements On February 2, 2016, the Company entered into an employment agreement with Jonathan F. Head, Ph.D. (“Dr. Head”) to serve as the Company’s Chief Executive Officer, the term of which runs for three years (from February 2, 2016 through February 1, 2019) and renews automatically for one year periods unless a written notice of termination is provided not less than 120 days prior to the automatic renewal date. The employment agreement with Dr. Head provides that Dr. Head’s salary for calendar year 2016 shall be $275,000 and for calendar year 2017 and for each calendar year thereafter during the term of the employment agreement with Dr. Head shall be an amount determined by the Board of Directors, which in no event shall be less than the annual salary that was payable by the Company to Dr. Head for the immediately preceding calendar year. On February 2, 2016, the Company entered into an employment agreement with Andrew Kucharchuk (“Mr. Kucharchuk) to serve as the Company’s President and Chief Financial Officer, the term of which runs for three years (from February 2, 2016 through February 1, 2019) and renews automatically for one year periods unless a written notice of termination is provided not less than 120 days prior to the automatic renewal date. The employment agreement with Mr. Kucharchuk provides that Mr. Kucharchuk’s salary for calendar year 2016 shall be $200,000 and for calendar year 2017 and for each calendar year thereafter during the term of the employment agreement with Mr. Kucharchuk shall be an amount determined by the Board of Directors, which in no event shall be less than the annual salary that was payable by the Company to Mr. Kucharchuk for the immediately preceding calendar year. The above executives shall be eligible for an annual target bonus payment in an amount equal to ten percent of his base salary (“Bonus”). The Bonus is determined based on the achievement of certain performance objectives of the Company as established by the Board of Directors. The Bonus may be greater or less than the target Bonus, based on the level of achievement of the applicable performance objectives.	NOTE 8 – COMMITMENTS AND CONTINCENGIES Lease Effective September 1, 2015, the Company leases its facilities under non-cancelable operating leases. The Company has the right to renew certain facility leases for an additional five years. Rent expense was $14,734 and $0 for the years ended December 31, 2015 and 2014, respectively. Future minimum lease payments under non-cancelable operating leases at December 31, 2015 are as follows: Years ending December 31, Amount 2016 $ 36,800 2017 36,800 2018 37,333 2019 38,400 2020 25,600 Total minimum non-cancelable operating lease payments $ 174,933

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	NOTE 8 – SUBSEQUENT EVENTS In July 2016, pursuant to a stock purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) dated October 20, 2015, whereby we have the right to sell to, and Lincoln Park is obligated to purchase, up to an $10 million in amounts of shares of the Company’s common stock, subject to certain limitations, from time to time, over the 36-month period, the Company issued 200,000 shares of its common stock to Lincoln Park for net proceeds of $41,280.	NOTE 9 - SUBSEQUENT EVENTS Common stock issued On January 1, 2016, the Company issued 60,000 shares of common stock valued at $.30 per common share or $18,000 to a director for services to be rendered on the Company’s board of directors. The shares were valued at the most recent cash price paid of $.30 per share. In connection with these shares, the Company recorded stock-based compensation of $18,000. In February 2016, pursuant to subscription agreements, the Company issued 36,000 shares of its common stock to investors for cash proceeds of $10,800. Employment agreements On February 2, 2016, the Company entered into an employment agreement with Jonathan F. Head, Ph.D. (“Dr. Head”) to serve as the Company’s Chief Executive Officer, the term of which runs for three years (from February 2, 2016 through February 1, 2019) and renews automatically for one year periods unless a written notice of termination is provided not less than 120 days prior to the automatic renewal date. The Employment Agreement with Dr. Head provides that Dr. Head’s salary for calendar year 2016 shall be $275,000 and for calendar year 2017 and for each calendar year thereafter during the term of the Employment Agreement with Dr. Head shall be an amount determined by the Board of Directors, which in no event shall be less than the annual salary that was payable by the Company to Dr. Head for the immediately preceding calendar year. On February 2, 2016, the Company entered into an employment agreement with Andrew Kucharchuk (“Mr. Kucharchuk) to serve as the Company’s President and Chief Financial Officer, the term of which runs for three years (from February 2, 2016 through February 1, 2019) and renews automatically for one year periods unless a written notice of termination is provided not less than 120 days prior to the automatic renewal date. The employment agreement with Mr. Kucharchuk provides that Mr. Kucharchuk’s salary for calendar year 2016 shall be $200,000 and for calendar year 2017 and for each calendar year thereafter during the term of the Employment Agreement with Mr. Kucharchuk shall be an amount determined by the Board of Directors, which in no event shall be less than the annual salary that was payable by the Company to Mr. Kucharchuk for the immediately preceding calendar year. The above executives shall be eligible for an annual target bonus payment in an amount equal to ten percent of his base salary (“Bonus”). The Bonus is determined based on the achievement of certain performance objectives of the Company as established by the Board of Directors. The Bonus may be greater or less than the target Bonus, based on the level of achievement of the applicable performance objectives.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Use of Estimates	Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates during the six months ended June 30, 2016 and 2015 include the useful life of property and equipment, assumptions used in assessing impairment of long-term assets, estimates of current and deferred income taxes and deferred tax valuation allowances and the fair value of non-cash equity transactions.	Use of estimates The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates during the year ended December 31, 2015 and December 31, 2014 include the useful life of property and equipment, assumptions used in assessing impairment of long-term assets, estimates of current and deferred income taxes and deferred tax valuation allowances and the fair value of non-cash equity transactions.
Fair Value of Financial Instruments and Fair Value Measurements	Fair value of financial instruments and fair value measurements The Company adopted the guidance of Accounting Standards Codification (“ASC”) 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: ● Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. ● Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. ● Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The carrying amounts reported in the consolidated balance sheets for cash, employee loans, prepaid expenses, loans payable, line of credit payable, payroll liabilities, and accounts payable and accrued liabilities, approximate their fair market value based on the short-term maturity of these instruments. The Company did not identify any assets or liabilities that are required to be presented on the consolidated balance sheets at fair value in accordance with ASC Topic 820. ASC 825-10 “ Financial Instruments ,	Fair value of financial instruments and fair value measurements The Company adopted the guidance of Accounting Standards Codification (“ASC”) 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: ● Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. ● Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. ● Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The carrying amounts reported in the consolidated balance sheets for cash, employee loans, prepaid expenses, loans payable, line of credit payable, payroll liabilities, and accounts payable and accrued liabilities, approximate their fair market value based on the short-term maturity of these instruments. The Company did not identify any assets or liabilities that are required to be presented on the consolidated balance sheets at fair value in accordance with ASC Topic 820. ASC 825-10 “ Financial Instruments ,
Cash and Cash Equivalent		Cash and Cash Equivalent For purposes of the consolidated statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less at the purchase date and money market accounts to be cash equivalents. At December 31, 2015 and 2014, the Company did not have any cash equivalents. The Company maintains its cash in bank and financial institution deposits that at times may exceed federally insured limits. At December 31, 2015, cash in bank exceeded federally insured limits. There were no balances in excess of FDIC insured levels as of December 31, 2014. The Company has not experienced any losses in such accounts through December 31, 2015 and 2014.
Property and Equipment		Property and equipment Property are stated at cost and are depreciated using the straight-line method over their estimated useful lives, which range from three to ten years. Leasehold improvements are depreciated over the shorter of the useful life or lease term including scheduled renewal terms. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.
Impairment of Long-lived Assets		Impairment of long-lived assets In accordance with ASC Topic 360, the Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.
Revenue Recognition		Revenue recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the purchase price is fixed or determinable and collectability is reasonably assured. For all revenue sources discussed below, in accordance ASC 605-45 “Principal Agent Considerations”, the Company recognizes revenue net of amounts retained by third party entities.
Federal and State Income Taxes		Federal and state income taxes The Company accounts for income tax using the liability method prescribed by ASC 740, “Income Taxes”. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. Prior to the June 3, 2015, the Company operated ONC as a limited liability company and passed all income and loss to each member based on their proportionate interest in ONC. In accordance with the generally accepted method of presenting limited liability company financial statements, the consolidated financial statements do not include the personal assets and liabilities of the members, including their obligation for income taxes on their distributive shares of net income of the LLCs, or any provision for federal income taxes prior to June 3, 2015. The Company follows the accounting guidance for uncertainty in income taxes using the provisions of Accounting Standards Codification (ASC) 740 “Income Taxes
Research and Development		Research and development Research and development costs incurred in the development of the Company’s products are expensed as incurred. For the years ended December 31, 2015 and 2014, research and development costs were $85,323 and $151,255, respectively, and are included in operating expenses on the accompanying consolidated statements of operations.
Stock-Based Compensation	Stock-based compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is recognized over the service period of the award.	Stock-based compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is recognized over the service period of the award.
Basic and Diluted Earnings Per Share	Basic and diluted earnings per share Pursuant to ASC 260-10-45, basic earnings per common share is computed by dividing income (loss) available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted income per share is computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. Diluted income (loss) per share reflects the potential dilution that could occur if securities were exercised or converted into common stock or other contracts to issue common stock resulting in the issuance of common stock that would then share in the Company’s income (loss) subject to anti-dilution limitations. Potentially dilutive common shares consist of common stock issuable for stock warrants (using the treasury stock method). These common stock equivalents may be dilutive in the future. All potentially dilutive common shares were excluded from the computation of diluted shares outstanding as they would have an anti-dilutive impact on the Company’s net losses and consisted of the following: June 30, 2016 June 30, 2015 Total stock warrants 2,694 2,694	Basic and diluted earnings per share Pursuant to ASC 260-10-45, basic earnings per common share is computed by dividing income (loss) available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted income per share is computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. Diluted income (loss) per share reflects the potential dilution that could occur if securities were exercised or converted into common stock or other contracts to issue common stock resulting in the issuance of common stock that would then share in the Company’s income (loss) subject to anti-dilution limitations. Potentially dilutive common shares consist of common stock issuable for stock warrants (using the treasury stock method). These common stock equivalents may be dilutive in the future. All potentially dilutive common shares were excluded from the computation of diluted shares outstanding as they would have an anti-dilutive impact on the Company’s net losses and consisted of the following: December 31, 2015 December 31, 2014 Total stock warrants 2,694 0
Recent Accounting Pronouncements	Recent accounting pronouncements In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern, In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes Income Taxes On January 5, 2016, the FASB issued ASU No. 2016-01 to amend the accounting guidance on the classification and measurement of financial instruments. The standard requires that all investments in equity securities, including other ownership interests, are carried at fair value through net income. This requirement does not apply to investments that qualify for equity method accounting or to those that result in consolidation of the investee or for which the entity has elected the predictability exception to fair value measurement. Additionally, the standard requires that the portion of the total fair value change caused by a change in instrument-specific credit risk for financial liabilities for which the fair value option has been elected would be recognized in other comprehensive income. Any accumulated amount remaining in other comprehensive income is reclassified to earnings when the liability is extinguished. The Company does not anticipate the guidance to have a material impact on its consolidated financial statements or notes to its consolidated financial statements. On February 25, 2016, the FASB issued ASU No. 2016-02 (“ASU 2016-02”) to amend the accounting guidance for leases. The accounting applied by a lessor is largely unchanged under ASU 2016-02. However, the standard requires lessees to recognize lease assets and lease liabilities for leases classified as operating leases on the balance sheet. Lessees will recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it will recognize lease expense for such leases generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and early adoption is permitted. The Company is currently assessing the impact of the guidance on its consolidated financial statements and notes to its consolidated financial statements. On March 30, 2016, the FASB issued ASU No. 2016-09 (“ASU 2016-09”) to amend the accounting guidance for share-based payment accounting. The areas for simplification in ASU 2016-09 involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016 Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.	Recent accounting pronouncements In June 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-12, “ Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period In August 2014, FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, In February 2015, the FASB issued ASU 2015-02, Consolidation In April 2015, the FASB issued ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30) In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes Income Taxes Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Anti-Dilutive Shares Outstanding	All potentially dilutive common shares were excluded from the computation of diluted shares outstanding as they would have an anti-dilutive impact on the Company’s net losses and consisted of the following: June 30, 2016 June 30, 2015 Total stock warrants 2,694 2,694	All potentially dilutive common shares were excluded from the computation of diluted shares outstanding as they would have an anti-dilutive impact on the Company’s net losses and consisted of the following: December 31, 2015 December 31, 2014 Total stock warrants 2,694 0

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	At December 31, 2015 and 2014, property and equipment consisted of the following: Useful Life 2015 2014 Leasehold improvements 10 Years $ 23,976 $ - Less: accumulated depreciation (13,274 ) - Property and equipment, net $ 10,702 $ 0

Convertible Promissory Note (Ta

Convertible Promissory Note (Tables)	6 Months Ended
	Jun. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Liabilities at Fair Value	During the six months ended June 30, 2016, the fair value of the derivative liabilities was estimated using the Black-Scholes option-pricing model with the following assumptions: Dividend rate 0 Term (in years) 0.92 to 1.0 years Volatility 366.97 % Risk-free interest rate 0.45% to 0.69 %
Schedule of Convertible Note	At June 30, 2016 and December 31, 2015, the Convertible Note consisted of the following: June 30, 2016 December 31, 2015 Principal amount $ 40,000 $ - Less: unamortized debt discount (35,833 ) - Convertible note payable, net $ 4,167 $ -

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Related Party Transactions [Abstract]
Schedule of Related Parties Activity	For the six months ended June 30, 2016, due from/(to) related parties’ activity consisted of the following: Foundation CEO CFO Total Balance due from (to) related parties at December 31, 2015 $ 3,200 $ 5,900 $ 8,700 ) $ 17,800 Working capital advances made 3,687 - 3,250 6,937 Repayments received (6,050 ) (5,900 ) (10,195 ) (22,145 ) Balance due from (to) related parties at June 30, 2016 $ 837 $ - $ 1,755 $ 2,592	For the year ended December 31, 2015 and 2014, due from/(to) related parties activity consisted of the following: Foundation CEO CFO Total Balance due from (to) related party at December 31, 2013 $ (30,000 ) $ - $ - $ (30,000 ) Working capital advances received (45,100 ) - - (45,100 ) Repayments made 29,000 - - 29,000 Balance due from (to) related party at December 31, 2014 (46,100 ) - - (46,100 ) Working capital advances received (48,350 ) (7,500 ) (4,600 ) (60,450 ) Repayments made 97,650 13,400 13,300 124,350 Balance due from (to) related party at December 31, 2015 $ 3,200 $ 5,900 $ 8,700 $ 17,800

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Effective Income Taxes and Reconciliation	The items accounting for the difference between income taxes at the effective statutory rate and the provision for income taxes for the years ended December 31, 2015 and 2014 were as follows: Years Ended December 31, 2015 2014 Income tax benefit at U.S. statutory rate of 34% $ (337,000 ) $ - State income taxes bene (79,000 ) - Stock-based compensation 7,000 Income tax effect during LLC period 36,000 - Change in valuation allowance 373,000 - Total provision for income tax $ - $ -
Schedule of Deferred Tax Assets	The Company’s approximate net deferred tax assets as of December 31, 2015 and 2014 were as follows: December 31, 2015 December 31, 2014 Deferred Tax Assets: Net operating loss carryforward $ 373,000 $ - Total deferred tax assets 373,000 - Valuation allowance (373,000 ) - Net deferred tax assets $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Summary of Future Minimum Lease Payments	Future minimum lease payments under non-cancelable operating leases at December 31, 2015 are as follows: Years ending December 31, Amount 2016 $ 36,800 2017 36,800 2018 37,333 2019 38,400 2020 25,600 Total minimum non-cancelable operating lease payments $ 174,933

Organization and Basis of Prese

Organization and Basis of Presentation (Details Narrative) (10K) - USD ($)	Aug. 20, 2015	Jun. 22, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Aug. 12, 2015
Capital stock, shares authorized									520,000,000
Common stock, shares authorized									500,000,000
Common stock, par value			$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, par value			$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized			20,000,000		20,000,000		20,000,000	20,000,000	20,000,000
Net loss			$ 580,068	$ 76,281	$ 1,024,408	$ 120,534	$ 990,396	$ 453,879
Net cash used in operating activities					750,810	$ 170,934	851,841	418,212
Accumulated deficit			$ 2,153,627		$ 2,153,627		$ 1,129,219	$ 138,823
Series A Preferred Stock [Member]
Preferred stock, par value			$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000,000		1,000,000		1,000,000		1,000,000	1,000,000
Preferred stock shares designating	1,000,000
Stock holder voting rights	Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for the taking of any corporate action.
ONC Shareholders [Member] | Series A Preferred Stock [Member]
Number of stock exchange for shares		1,000,000
Percentage of outstanding preferred stock		100.00%
Share Exchange Agreement [Member] | ONC Shareholders [Member]
Percentage of acquired of common stock shares issued and outstanding		100.00%
Number of stock exchange for shares		47,000,000
Percentage of outstanding common stock		91.30%
Reverse stock split		1-for-139.2328 reverse stock split
Number of share reduction of issued and outstanding share of prior to exchange shares		4,493,390

Organization and Nature of Op25

Organization and Nature of Operations (Details Narrative) (10Q) - USD ($)	Aug. 20, 2015	Jun. 22, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Aug. 12, 2015
Capital stock, shares authorized									520,000,000
Common stock, shares authorized									500,000,000
Common stock, par value			$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, par value			$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized			20,000,000		20,000,000		20,000,000	20,000,000	20,000,000
Net loss			$ 580,068	$ 76,281	$ 1,024,408	$ 120,534	$ 990,396	$ 453,879
Net cash used in operating activities					750,810	170,934	851,841	418,212
Accumulated deficit			2,153,627		2,153,627		1,129,219	138,823
Revenues								$ 254
Series A Preferred Stock [Member]
Preferred stock, par value			$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000,000		1,000,000		1,000,000		1,000,000	1,000,000
Preferred stock shares designating	1,000,000
Stock holder voting rights	Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for the taking of any corporate action.
ONC Shareholders [Member] | Series A Preferred Stock [Member]
Number of stock exchange for shares		1,000,000
Percentage of outstanding preferred stock		100.00%
Share Exchange Agreement [Member] | ONC Shareholders [Member]
Percentage of acquired of common stock shares issued and outstanding		100.00%
Number of stock exchange for shares		47,000,000
Percentage of outstanding common stock		91.30%
Reverse stock split		1-for-139.2328 reverse stock split
Number of share reduction of issued and outstanding share of prior to exchange shares		4,493,390

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Details Narrative) (10K) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Research and development costs	$ 50,449	$ 14,133	$ 80,535	$ 14,148	$ 85,323	$ 151,255

Summary of Significant Accoun27

Summary of Significant Accounting Policies - Schedule of Anti-Dilutive Shares Outstanding (Details) (10K) - shares	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Total stock warrants	2,694	2,694	2,694	0

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Schedule of Anti-Dilutive Shares Outstanding (Details) (10Q) - shares	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Total stock warrants	2,694	2,694	2,694	0

Property and Equipment (Details

Property and Equipment (Details Narrative) (10K) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 274	$ 0

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) (10K) - USD ($)	12 Months Ended
	Dec. 31, 2015	Jun. 30, 2016	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Leasehold improvements, Useful Life	10 years
Leasehold improvements	$ 23,976
Less: accumulated depreciation	(13,274)
Property and equipment, net	$ 10,702	$ 10,153

Line of Credit (Details Narrati

Line of Credit (Details Narrative) (10K) - USD ($)	Oct. 31, 2014	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Line of credit		$ 57,741		$ 49,708	$ 34,981
Line of credit interest rate		5.20%	5.20%	5.20%	4.95%
Available to borrow under the line of credit		$ 42,259		$ 50,292	$ 65,019
Weighted average interest rate		5.20%		4.95%	4.95%
Prime Rate [Member]
Line of credit interest rate				1.70%
Revolving Credit Facility [Member] | Regions Bank [Member]
Line of credit	$ 100,000
Line of credit expiration date	Oct. 27, 2017

Line of Credit (Details Narra32

Line of Credit (Details Narrative) (10Q) - USD ($)	Oct. 31, 2014	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Line of credit		$ 57,741		$ 49,708	$ 34,981
Line of credit interest rate		5.20%	5.20%	5.20%	4.95%
Available to borrow under the line of credit		$ 42,259		$ 50,292	$ 65,019
Weighted average interest rate		5.20%		4.95%	4.95%
Prime Rate [Member]
Line of credit interest rate				1.70%
Revolving Credit Facility [Member] | Regions Bank [Member]
Line of credit	$ 100,000
Line of credit expiration date	Oct. 27, 2017

Convertible Promissory Note (De

Convertible Promissory Note (Details Narrative) (10Q) - USD ($)	May 23, 2016	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Convertible promissory note		$ 40,000	$ 40,000
Conversion price, percentage	58.00%
Lowest trading price	$ 0.10
Convertible debt conversion description	Then an additional discount of five percent (5%) will be factored into the VCP until the Convertible Note is no longer outstanding (resulting in a discount rate of 47% assuming no other adjustments are triggered hereunder). In the event that shares of the Company’s common stock are not deliverable via DWAC following the conversion of any amount thereunder, an additional five percent (5%) discount shall be factored into the VCP until the Convertible Note is no longer outstanding (resulting in a discount rate of 47% assuming no other adjustments are triggered hereunder).
Embedded derivative liability		76,012	76,012
Proceeds from convertible note			36,000	$ 100,000	$ 100,000
Initial derivative expense		0	40,012
Change in fair value of derivative liabilities		104,494	104,494
Amortization of debt discounts		$ 4,167	$ 4,167
Convertible Note [Member]
Weighted average interest rate		8.00%	8.00%
Initial 30 Day Period [Member]
Debt instrument, redemption price, percentage	115.00%
31st to 60th Day [Member]
Debt instrument, redemption price, percentage	120.00%
61st to 90th Day [Member]
Debt instrument, redemption price, percentage	125.00%
91st to 120th Day [Member]
Debt instrument, redemption price, percentage	130.00%
120th to 150th Day [Member]
Debt instrument, redemption price, percentage	135.00%
151st to l80th Day [Member]
Debt instrument, redemption price, percentage	140.00%
Crown Bridge Partners, LLC [Member]
Convertible promissory note	$ 40,000
Debt maturity date	May 22, 2017
Debt interest rate	8.00%
Bear interest	22.00%

Convertible Promissory Note - S

Convertible Promissory Note - Schedule of Derivative Liabilities at Fair Value (Details) (10Q)	6 Months Ended
	Jun. 30, 2016
Dividend rate	0.00%
Volatility	366.97%
Minimum [Member]
Term (in years)	11 months 1 day
Risk-free interest rate	0.45%
Maximum [Member]
Term (in years)	1 year
Risk-free interest rate	0.69%

Convertible Promissory Note -35

Convertible Promissory Note - Schedule of Convertible Note (Details) (10Q) - USD ($)	Jun. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
Principal amount	$ 40,000
Less: unamortized debt discount	(35,833)
Convertible note payable, net	$ 4,167

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Parties Activity (Details) (10K) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Beginning Balance due from (to) related party	$ 17,800	$ (46,100)	$ (46,100)	$ (30,000)
Working capital advances received	6,937		(60,450)	(45,100)
Repayments made		11,000	124,350	29,000
Ending Balance due from (to) related party	2,592		17,800	(46,100)
Foundation [Member]
Beginning Balance due from (to) related party	3,200	(46,100)	(46,100)	(30,000)
Working capital advances received	3,687		(48,350)	(45,100)
Repayments made	(6,050)		97,650	29,000
Ending Balance due from (to) related party	837		3,200	(46,100)
CEO [Member]
Beginning Balance due from (to) related party	5,900
Working capital advances received			(7,500)
Repayments made	(5,900)		13,400
Ending Balance due from (to) related party			5,900
CFO [Member]
Beginning Balance due from (to) related party	8,700
Working capital advances received	3,250		(4,600)
Repayments made	(10,195)		13,300
Ending Balance due from (to) related party	$ 1,755		$ 8,700

Related Party Transactions - 37

Related Party Transactions - Schedule of Related Parties Activity (Details) (10Q) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Beginning Balance due from (to) related party	$ 17,800	$ (46,100)	$ (46,100)	$ (30,000)
Working capital advances received	6,937		(60,450)	(45,100)
Repayments received		11,000	124,350	29,000
Ending Balance due from (to) related party	2,592		17,800	(46,100)
Foundation [Member]
Beginning Balance due from (to) related party	3,200	(46,100)	(46,100)	(30,000)
Working capital advances received	3,687		(48,350)	(45,100)
Repayments received	(6,050)		97,650	29,000
Ending Balance due from (to) related party	837		3,200	(46,100)
CEO [Member]
Beginning Balance due from (to) related party	5,900
Working capital advances received			(7,500)
Repayments received	(5,900)		13,400
Ending Balance due from (to) related party			5,900
CFO [Member]
Beginning Balance due from (to) related party	8,700
Working capital advances received	3,250		(4,600)
Repayments received	(10,195)		13,300
Ending Balance due from (to) related party	$ 1,755		$ 8,700

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) (10K) - USD ($)	May 13, 2016	Jan. 02, 2016	Nov. 18, 2015	Oct. 20, 2015	Sep. 02, 2015	Aug. 20, 2015	Dec. 31, 2015	Nov. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Aug. 12, 2015
Preferred stock, shares authorized							20,000,000		20,000,000		20,000,000		20,000,000	20,000,000	20,000,000
Number of share exchange during period													47,000,000
Percentage of outstanding shares													91.30%
Common stock issued for cash													$ 1,361,523
Common stock issued for cash, shares													4,493,390
Common stock issued for convertible debt													$ 100,000
Common stock issued for convertible debt, shares													200,000
Common stock issued for services	$ 68,000	$ 18,000									$ 68,000		$ 18,000
Common stock issued for services, shares		60,000	60,000										60,000
Common stock value per share			$ 0.30
Stock-based compensation	$ 17,000	$ 18,000	$ 18,000								35,000		$ 18,000
Offering costs													(205,000)
Procceds from sale of stock													$ 95,000
Investor [Member]
Common stock issued for cash							$ 1,266,523
Common stock issued for cash, shares							4,221,085
OncBioMune, Inc [Member]
Percentage of ownership interest acquired					100.00%
Lincoln Park [Member]
Percentage of outstanding shares				4.99%
Common stock value per share				$ 0.30				$ 0.30
Number of shares purchased under the agreement				333,334				333,334
Value of shares purchased under agreement				$ 100,000				$ 95,000
Sale of stock description				Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right to sell to, and Lincoln Park is obligated to purchase, up to an additional $10.0 million in amounts of shares, as described below, of the Company’s common stock, subject to certain limitations, from time to time, over the 36-month period commencing on the date that a registration statement, which the Company agreed to file with the Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus in connection therewith is filed. The Company may direct Lincoln Park, at its sole discretion and subject to certain conditions, to purchase up to 50,000 shares of Common Stock on any business day (such purchases, “Regular Purchases”), provided that at least one business day has passed since the most recent purchase, and provided, however that Lincoln Park’s committed obligation under any single Regular Purchase shall not exceed Fifty Thousand Dollars ($50,000), provided that the amount the Company may sell to Lincoln Park under a single Regular Purchase may increase under certain circumstances as described in the Purchase Agreement but in no event will the amount of a single Regular Purchase exceed Five Hundred Thousand Dollars ($500,000). The purchase price of shares of Common Stock related to the future funding will be based on the prevailing market prices of such shares at the time of sales. In addition, the Company may direct Lincoln Park to purchase additional amounts as accelerated purchases if on the date of a Regular Purchase the closing sale price of the Common Stock is not below the threshold price as set forth in the Purchase Agreement. The Company’s sales of shares of Common Stock to Lincoln Park under the Purchase Agreement are limited to no more than the number of shares that would result in the beneficial ownership by Lincoln Park and its affiliates, at any single point in time, of more than 4.99% of the then outstanding shares of the Common Stock.
Shares issued for commitment fee				1,000,000				1,000,000
Value of shares issued for commitment fee								$ 300,000
Offering costs								$ (300,000)
Series A Preferred Stock [Member]
Preferred stock, shares authorized						20,000,000	1,000,000		1,000,000		1,000,000		1,000,000	1,000,000
Preferred stock shares designating						1,000,000
Stock holder voting rights						Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for the taking of any corporate action.
Number of share exchange during period					1,000,000
Percentage of outstanding shares					100.00%
Common stock issued for cash
Common stock issued for cash, shares
Common stock issued for services
Common stock issued for services, shares

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) (10Q) - USD ($)	May 13, 2016	Jan. 02, 2016	Nov. 18, 2015	Sep. 02, 2015	Aug. 20, 2015	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Aug. 12, 2015
Preferred stock, shares authorized						20,000,000			20,000,000		20,000,000	20,000,000	20,000,000
Number of share exchange during period											47,000,000
Percentage of outstanding shares											91.30%
Common stock issued for services	$ 68,000	$ 18,000							$ 68,000		$ 18,000
Common stock issued for services, shares		60,000	60,000								60,000
Common stock value per share	$ 0.34	$ 0.30
Stock-based compensation	$ 17,000	$ 18,000	$ 18,000						35,000		$ 18,000
Pay consultant a monthly fee	$ 4,000					$ 184,096		$ 14,500	$ 311,099	$ 27,250	$ 213,838	$ 37,293
Number of issue shares during period consultant/affiliates	200,000
Prepaid expenses	$ 51,000
Common stock issued for cash, shares											4,493,390
Common stock issued for cash											$ 1,361,523
Investors [Member]
Common stock issued for cash, shares							68,382
Common stock issued for cash							$ 46,801
November 15, 2016 [Member]
Common stock issued for services	100,000
Pay consultant a monthly fee	$ 7,500
Series A Preferred Stock [Member]
Preferred stock, shares authorized					20,000,000	1,000,000			1,000,000		1,000,000	1,000,000
Preferred stock shares designating					1,000,000
Stock holder voting rights					Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for the taking of any corporate action.
Number of share exchange during period				1,000,000
Percentage of outstanding shares				100.00%
Common stock issued for services
Common stock issued for services, shares
Number of issue shares during period consultant/affiliates											1,000,000
Common stock issued for cash, shares
Common stock issued for cash

Income Taxes (Details Narrative

Income Taxes (Details Narrative) (10K)	12 Months Ended
	Dec. 31, 2015USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 888,100
Change in valuation allowance	$ 373,000
Loss carryforward expiration year	2,035

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Taxes and Provision (Details) (10K) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income tax benefit at U.S. statutory rate of 34%	$ (337,000)
State income taxes bene	(79,000)
Stock-based compensation	7,000
Income tax effect during LLC period	36,000
Change in valuation allowance	373,000
Total provision for income tax
Percentage of statutory rate	34.00%

Income Taxes - Schedule of Def

Income Taxes - Schedule of Deferred Tax Assets (Details) (10K) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 373,000
Total deferred tax assets	373,000
Valuation allowance	(373,000)
Net deferred tax asset

Commitments and Contingencies43

Commitments and Contingencies (Details Narrative) (10K) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 14,734	$ 0

Commitments and Contingencies -

Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details) (10K)	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 36,800
2,017	36,800
2,018	37,333
2,019	38,400
2,020	25,600
Total minimum non-cancelable operating lease payments	$ 174,933

Commitments (Details Narrative)

Commitments (Details Narrative) (10Q)	Feb. 02, 2016USD ($)
Jonathan F. Head, Ph.D [Member]
Salary payable	$ 275,000
Andrew Kucharchuk Chief Financial Officer [Member]
Salary payable	$ 200,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) (10K) - USD ($)	May 13, 2016	Feb. 02, 2016	Jan. 02, 2016	Jan. 02, 2016	Nov. 18, 2015	Feb. 29, 2016	Dec. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Common stock issued for services	$ 68,000			$ 18,000				$ 68,000		$ 18,000
Common stock issued for services, shares				60,000	60,000					60,000
Common stock value per share					$ 0.30
Common stock issued for cash, shares										4,493,390
Common stock issued for cash										$ 1,361,523
Investor [Member]
Common stock issued for cash, shares							4,221,085
Common stock issued for cash							$ 1,266,523
Subsequent Event [Member]
Common stock issued for services			$ 18,000
Common stock issued for services, shares			60,000
Common stock value per share			$ 0.30	$ 0.30
Subsequent Event [Member] | Investor [Member]
Common stock issued for cash, shares						36,000
Common stock issued for cash						$ 10,800
Subsequent Event [Member] | Dr. Head [Member] | 2016 [Member]
Annual salary		$ 275,000
Subsequent Event [Member] | Mr. Kucharchuk's [Member] | 2016 [Member]
Annual salary		$ 200,000

Subsequent Events (Details Na47

Subsequent Events (Details Narrative) (10Q) - USD ($)	May 13, 2016	Jul. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Number of common stock shares issued	200,000
Proceeds from issuance of common stock			$ 46,801		$ 1,361,523
Subsequent Event [Member] | Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]
Additional common stock purchased		$ 10,000,000
Number of common stock shares issued		200,000
Proceeds from issuance of common stock		$ 41,280